[A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study)].
Level 5 - mechanism / opinion, no new human data
Narrative review and historical summary of peptide development and application without primary trial data.
What was done
This paper summarizes 15 years of preclinical research and clinical experience with the ACTH(4-10) peptide analog Semax. The abstract describes evaluations of intranasal administration at doses of 0.015 to 0.050 mg/kg in animal models, healthy men performing under extreme conditions, and patients with various central nervous system disorders.
What was found
The abstract reports that Semax stimulated operative memory and attention, improved cerebral circulation, and enhanced hypoxia resistance for 20 to 24 hours following intranasal administration. It notes positive therapeutic effects in patients with central nervous system diseases and healthy men under extreme stress, with no adverse reactions or complications observed. No primary numerical data, sample sizes, or p-values are reported in the abstract.
Why it matters
This review outlines the development and broad therapeutic claims made for Semax as a nootropic and neuroprotective peptide in Russian medical practice.
Limits
The abstract provides only high-level narrative assertions without quantitative outcomes, sample sizes, control groups, blinding protocols, or statistical analysis.
Cited by
- partial Semax improves cognitive function.